(Credit-Canva)
The current measles outbreak has gripped US states like Texas and New Mexico leaving people worried whether it would become a new pandemic. According to the Texas Department of State Health Services as of February 21, 90 cases were diagnosed in the last month in the South Plains area, with at least 77 of them were reported in children and teens under 17.
Measles is highly contagious and can be deadly. The outbreak, which started spreading in late January, has resulted in multiple hospitalizations, with at least nine confirmed cases and three probable cases as of early February. Health officials caution that at least one in five infected individuals will have to be hospitalized, highlighting the severity of the situation.
Misinformation surrounding vaccines and with the new Trump administration anti-vaccine campaigs, has causing parents to hesitate or refuse vaccination.
Furthermore, the country down under Australia is also witnessing a surge in measles cases as health officials in Sydney have issued an urgent alert, urging residents to watch for measles symptoms after an infected individual visited several places in Sydney over the last seven days.
Authorities report that the traveller had returned from South East Asia where there are ongoing outbreaks of measles.
Key symptoms of measles include fever, a runny nose, sore eyes, and a cough. Typically, a red, blotchy rash appears three to four days later, spreading from the head down to the body. Symptoms can manifest between 7 and 18 days after exposure.
Anyone who experiences these symptoms after potential exposure should immediately contact their doctor or emergency department. It is crucial to call ahead before visiting to avoid potentially exposing others in the waiting room. Dr. Selvey also highlighted that ongoing measles outbreaks are occurring in various parts of the world, making awareness and prompt action essential.
According to CDC everyone should get the MMR vaccine. It protects you from measles, mumps, and rubella. Getting vaccinated helps stop these diseases from spreading. There are two safe MMR vaccines available. They work the same way, so it doesn't matter which one you get. Kids can also get a shot that protects against chickenpox too, but this is only for children.
All children should get two MMR shots. The first shot should be given when they are between 12 and 15 months old. The second shot should be given when they are between 4 and 6 years old. If needed, the second shot can be given earlier, but it must be at least 28 days after the first shot.
Students going to college or other schools after high school, need two shots if they are not already immune. The shots must be at least 28 days apart.
Most adults need at least one MMR shot. Some adults need two shots, especially those who work in healthcare, travel a lot, or go to college. These people should get two shots, with 28 days between them.
Anyone traveling to other countries should make sure they are protected. Babies 6 to 11 months old should get one shot before traveling. Kids 12 months and older, teens, and adults need two shots, with 28 days between them.
People who work in healthcare should have proof that they are immune to measles, mumps, and rubella. If they are not immune, they need two MMR shots, spaced 28 days apart.
Women who might get pregnant should talk to their doctor about the MMR vaccine. It's safe to get the shot while breastfeeding.
Credit: AI
Singapore will increase surveillance of three deadly infectious diseases from October 31, needing doctors and other healthcare professionals to report all suspected and confirmed cases to the authorities.
The diseases include Marburg virus disease, Lassa fever and Crimean-Congo haemorrhagic fever (CCHF). All the three can lead to severe illness, and in extreme cases, they can even be fatal.
However, Singapore's Communicable Diseases Agency (CDA) has said the current risk posed by these diseases to the country remains low.
The move comes after amendments to Singapore's Infectious Diseases Act in September. The three diseases will be added to the list of prescribed infectious diseases, making notification of suspected and confirmed cases a legal requirement.
The authorities aim to detect these diseases earlier to foster a swift public health response, which includes isolation and tracing contacts.
The CDA said it has been monitoring the three diseases for some time, “as all three diseases are viral haemorrhagic fevers that can cause severe illness and have the potential for human-to-human transmission”.
A CDA spokeswoman told The Straits Times, “While there has been no change to the risk level from these three diseases, which currently remains low, they have been added to the IDA to strengthen our overall surveillance and preparedness efforts.”
From October 31, doctors and laboratories will be legally required to notify the authorities of suspected as well as confirmed cases of the three diseases. The CDA said it continuously monitors infectious disease developments both locally and internationally.
“As part of our preparedness efforts, CDA periodically reviews and updates the list of infectious diseases under the IDA to ensure that Singapore remains ready to respond to infectious disease risks,” the agency's spokeswoman said.
The three diseases will also be added to Singapore's list of “dangerous infectious diseases”, bringing the total to eight.
The five already listed are Ebola disease, Middle East respiratory syndrome coronavirus infection (MERS-CoV), plague, severe acute respiratory syndrome (SARS) and yellow fever.
Also read: People With Rare Diseases Have Higher Recorded COVID-19 Rates: UK Study Based On 62.5 Million People
Marburg virus disease, Lassa fever and Crimean-Congo haemorrhagic fever belong to a group of viral illnesses that can cause severe complications, including bleeding and organ complications in some patients.
Their routes of transmission differ, making timely diagnosis, reporting and anti-spread measures crucial.
According to the World Health Organization (WHO), there are currently no approved vaccines or specific treatments for any of the three diseases, but vaccine development is under way for Lassa fever and Marburg virus disease. The diseases also differ in their geographical distribution, typical severity and how they spread.
Crimean-Congo haemorrhagic fever is mainly transmitted through bites from infected ticks or contact with infected livestock. It can also spread through exposure to the blood or other bodily fluids of an infected person.
Symptoms can begin suddenly and include fever, muscle pain, dizziness, sore eyes and sensitivity to light. In severe cases, patients may develop liver, kidney or lung failure. According to WHO, the fatality rate can be as high as 40%.
Also read: GLP-1 Drugs May Lower Risk Of Heart Complications, Infections After Surgery
Lassa fever is mainly found in parts of West Africa. People can become infected through contact with food or household items contaminated with the urine or faeces of infected rodents. Human-to-human transmission can also occur through direct contact with an infected person's blood or bodily fluids.
Most infections cause no symptoms or only mild illness. Symptoms can include fever, sore throat, muscle pain, nausea, vomiting and diarrhoea. Severe cases may present with facial swelling, bleeding and low blood pressure.
The overall fatality rate is at around 1%, but it can rise significantly among patients hospitalised with severe illness.
Lassa fever can also have serious consequences during pregnancy. According to the information cited by The Straits Times, foetal death rates can exceed 80% in the third trimester, while maternal death rates can exceed 30%.
Hearing loss is another possible complication. Up to 25% of patients may experience hearing loss after recovering from the infection, and many do not regain their hearing.
Marburg virus disease is a rare but severe illness. Egyptian fruit bats are considered its natural reservoir, and infection can occur after exposure to infected animals or environments contaminated by them.
The disease can also spread between people through direct contact with the blood or other bodily fluids of an infected person, or through contaminated materials.
Symptoms often begin with sudden high fever, severe headache and muscle aches. Some patients develop bleeding, confusion and other serious complications. The fatality rate is around 50%, according to the WHO.
Credit: AI
Individuals diagnosed with rare diseases had higher COVID-19 rates than people who did not have them. As per a study analysing health records of 62.5 million people in England, there were significant differences in infections recorded across ethnic groups and individual rare diseases.
Published in Scientific Reports recently, the study analysed 406 rare diseases with the help of healthcare records from the National Health Service (NHS) in England.
Of the 62.5 million people included in the analysis, around 1.05 million, or 1.7%, had at least one of the 406 rare diseases.
COVID-19 infections were reported in around 32.8% of people with a rare disease, compared with 29% of those without one. Even though the difference between the two figures is not far from each other, it makes us stop and think.
According to the study researchers, the findings provide a country-wide picture of rare disease rates and incidence of COVID-19 infections across various ethnic groups.
The study found that COVID-19 infection rates differed significantly depending on the rare disease. Among the 25 most common rare diseases, infection rates ranged from 24.6% to 41.2%.
Four conditions had recorded infection rates below 30%: congenital laryngomalacia, at 24.6%; retinopathy of prematurity, at 26.5%; polymyalgia rheumatica, at 27.1%; and infantile apnoea, at 29.9%. The remaining 21 conditions had recorded infection rates between 30% and 50%.
These differences highlight an important point that people with rare diseases should not be treated as one uniform group, especially when it comes to their COVID experience.
However, the study did not establish that every person with a rare disease had a higher risk of contracting the virus, nor did it show that rare diseases necessarily led to more severe COVID-19.
The researchers also identified differences in COVID-19 infection rates among ethnic groups within the rare disease occurrence.
The highest rates were observed among people classified as White British, at 33.7%, and those in the broader White category used by the Office for National Statistics (ONS), at 33.5%.
Lower rates were recorded among several other groups, including Black African people, at 23.8%; Gypsy or Irish Traveller people, at 24.1%; Bangladeshi people, at 27.2%; and Pakistani people, at 27.7%.
The researchers said that this pattern was different from trends in the general population, where ethnic minority groups experienced an uneven burden of COVID-19.
Apart from COVID-19 infection, the study mapped 406 rare diseases across various ethnic groups. The researchers found variations in how frequently each condition was recorded.
Some of these differences became clearer when broad ethnic categories were divided into more specific groups. For example, discoid lupus erythematosus was more prevalent among Black Caribbean people than among Black African people.
The researchers also found that polymyalgia rheumatica was more prevalent among White people than Asian or Asian British and Black or Black British populations.
Also read: World Breast Cancer Day 2026: Life After Breast Cancer, The Fear No One Sees
The researchers carried out a cross-sectional analysis using NHS England’s Secure Data Environment, linking primary care, hospital and mortality records for people alive on July 31, 2023.
They estimated the prevalence of 406 rare diseases and examined COVID-19 infections across the overall population, individual rare diseases and ethnic groups. The analysis used both six ONS ethnic categories and 19 more detailed NHS ethnicity classifications.
The study’s large population base allowed the researchers to examine conditions that can be difficult to investigate because each rare disease affects relatively few people.
The researchers said the national estimates provide a baseline for understanding rare disease rates and COVID-19 cases across different populations in England. The findings may help inform future research and support efforts towards earlier diagnosis and better healthcare.
Credit: AI
Nearly 94% of tuberculosis (TB) patients in an Indian study conducted in Bengaluru reported anxiety symptoms, while 77.3% showed signs of depression. The findings focus on the mental health toll that comes with TB. It also sheds light on the need to include psychological support in routine treatment of tuberculosis.
The cross-sectional study, conducted with 66 adults at the Yeshwanthpur Tuberculosis Unit in Bengaluru, found that 56.1% had moderate to severe anxiety symptoms, while 46.9% had moderate to severe depressive symptoms. Nearly half of the participants experienced symptoms of both conditions.
The study was conducted by Dr. Pavithra Cheluvaraj, Dr. Vishnu C. Sudhakaran, Dr. Babitha Rajan and Anjana Sasikumar Nair from the Department of Community Medicine at Ramaiah Medical College.
The researchers examined the patients using the Patient Health Questionnaire-9 (PHQ-9) and the Generalised Anxiety Disorder-7 (GAD-7) scales.
Stigma linked with TB, fear of transmitting the infection to family members and existing health conditions may contribute to anxiety and depression among patients, Dr. Pavithra told Bangalore Mirror.
TB treatment can also entail a prolonged course of medication and regular follow-up. Psychological distress may make it harder for patients to continue treatment or seek timely care.
According to Dr. Pavithra, anxiety and depression if left untreated could affect the course of TB treatment. Patients experiencing psychological distress may delay starting treatment or stop taking their medication, which could compromising recovery and increasing the risk of drug resistance.
“If there is delay in diagnosis or treatment, the person can spread the disease,” she said.
Also read: You May Be Carrying TB, And Not Know Until It Gets Worse
The researchers used two standardised screening tools to assess symptoms of depression and anxiety.
The PHQ-9 measures depressive symptoms, while the GAD-7 tests for symptoms of anxiety. The study found that 51 of the 66 participants had symptoms linked with depression, and 62 had symptoms that indicated anxiety.
Moderate to severe symptoms were found in 31 participants for depression and 37 for anxiety. These screening results indicate the need for further clinical assessment. The findings are merely observations and they do not mean that every participant had a confirmed psychiatric diagnosis of anxiety and depression.
Additionally, the study was based on 66 adults in one tuberculosis unit in Bengaluru, so its findings cannot represent all TB patients in India.
But the high percentage of participants who reported symptoms of anxiety and depression suggest that there is need for better integration of mental health screening into TB treatment.
The researchers recommended routine screening for depression and anxiety when patients are diagnosed with TB and during follow-up visits. They also called for counselling and referrals for patients with more severe symptoms.
They say that identifying psychological distress early may help doctors connect patients with appropriate support while they receive treatment for the infection.
Even though this study is based on a small sample, it speaks about the long-term effects of the disease on mental health. TB is a global health crisis, which means this study warrants further investigation and action.
According to the WHO’s Global Tuberculosis Report 2025, in 2024, more than ten million people across the globe developed TB while more than 1.2 million lost their lives to the disease.
Currently, India bears the lion's share of TB burden compared to other countries. Uneven access to drug-resistant TB treatment, financial hardships, stigma, prolonged treatment are some of the factors that may contribute to deteriorating mental health of TB patients.
© $2026 Times Horizon Private Limited